Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japan's Kyowa Hakko Kirin Tests New Antibody Type For Many Cancers

This article was originally published in PharmAsia News

Executive Summary

Kyowa Hakko Kirin of Japan says it has begun U.S. clinical trials on a cancer drug that works similarly to targeted antibodies, but without their side effects, such as hair loss. The firm hopes to have the drug on the market late next year. The drug is based on a newly discovered synthetic compound that interferes with a protein responsible for the proliferation of many types of cancer cells. The company also is counting on the drug to provide the benefits of antibodies, but with a low-cost manufacturing process unlike the normal process that requires expensive and special manufacturing equipment. (Click here for more - a subscription may be required
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC072481

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel